Gene therapy, cell transplantation and stroke

Cesario V. Borlongan, Christina Fournier, Christine E. Stahl, Guolong Yu, Lin Xu, Noriyuki Matsukawa, Mary Newman, Takao Yasuhara, Koichi Hara, David C Hess, Paul R. Sanberg

Research output: Contribution to journalReview article

17 Citations (Scopus)

Abstract

The use of neuroteratocarcinoma cells for transplantation therapy in stroke has emerged as a strategy for cell replacement therapy that has begun its transition from basic science laboratories to a clinical setting. Procurement logistics and novel neuroprotective functions associated with these cells allow neuroteratocarcmoma cells to serve as efficacious alternatives to using fetal cells as donor cell grafts for stroke therapy, although the optimal transplantation regimen must still be determined. In particular, the limitations of current stroke treatments and management reveal an urgent need to examine the efficacy of experimental treatments, such as neural transplantation, in order to develop better treatment therapies. This chapter will discuss the characteristics of NT2N cells, the role of the host brain microenvironment, the need for more rigorous laboratory research and clinical trials for the intracerebral transplantation of NT2N cells in stroke, the mechanisms underlying the grafts' beneficial effects, and the need for immunosuppression. This chapter will highlight some of the most recent findings regarding NT2N cells.

Original languageEnglish (US)
Pages (from-to)1090-1100
Number of pages11
JournalFrontiers in Bioscience
Volume11
Issue number1 P.889-1198
DOIs
StatePublished - Feb 23 2006

Fingerprint

Gene therapy
Cell Transplantation
Grafts
Genetic Therapy
Stroke
Clinical laboratories
Transplantation (surgical)
Research laboratories
Logistics
Brain
Cell- and Tissue-Based Therapy
Transplantation
Transplants
Therapeutics
Immunosuppression
Clinical Trials
Research

Keywords

  • Cancer
  • Gene therapy
  • Intracerebral Transplantation
  • Nervous system
  • Neuron
  • Neuroprotection
  • Neuroteratocarcinoma Cells
  • NT2N
  • Review
  • Stroke
  • Therapeutic
  • Treatment
  • Tumor

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Microbiology(all)

Cite this

Borlongan, C. V., Fournier, C., Stahl, C. E., Yu, G., Xu, L., Matsukawa, N., ... Sanberg, P. R. (2006). Gene therapy, cell transplantation and stroke. Frontiers in Bioscience, 11(1 P.889-1198), 1090-1100. https://doi.org/10.2741/1865

Gene therapy, cell transplantation and stroke. / Borlongan, Cesario V.; Fournier, Christina; Stahl, Christine E.; Yu, Guolong; Xu, Lin; Matsukawa, Noriyuki; Newman, Mary; Yasuhara, Takao; Hara, Koichi; Hess, David C; Sanberg, Paul R.

In: Frontiers in Bioscience, Vol. 11, No. 1 P.889-1198, 23.02.2006, p. 1090-1100.

Research output: Contribution to journalReview article

Borlongan, CV, Fournier, C, Stahl, CE, Yu, G, Xu, L, Matsukawa, N, Newman, M, Yasuhara, T, Hara, K, Hess, DC & Sanberg, PR 2006, 'Gene therapy, cell transplantation and stroke', Frontiers in Bioscience, vol. 11, no. 1 P.889-1198, pp. 1090-1100. https://doi.org/10.2741/1865
Borlongan CV, Fournier C, Stahl CE, Yu G, Xu L, Matsukawa N et al. Gene therapy, cell transplantation and stroke. Frontiers in Bioscience. 2006 Feb 23;11(1 P.889-1198):1090-1100. https://doi.org/10.2741/1865
Borlongan, Cesario V. ; Fournier, Christina ; Stahl, Christine E. ; Yu, Guolong ; Xu, Lin ; Matsukawa, Noriyuki ; Newman, Mary ; Yasuhara, Takao ; Hara, Koichi ; Hess, David C ; Sanberg, Paul R. / Gene therapy, cell transplantation and stroke. In: Frontiers in Bioscience. 2006 ; Vol. 11, No. 1 P.889-1198. pp. 1090-1100.
@article{8f80cf31bb3c4222b5bf97fa3321fd20,
title = "Gene therapy, cell transplantation and stroke",
abstract = "The use of neuroteratocarcinoma cells for transplantation therapy in stroke has emerged as a strategy for cell replacement therapy that has begun its transition from basic science laboratories to a clinical setting. Procurement logistics and novel neuroprotective functions associated with these cells allow neuroteratocarcmoma cells to serve as efficacious alternatives to using fetal cells as donor cell grafts for stroke therapy, although the optimal transplantation regimen must still be determined. In particular, the limitations of current stroke treatments and management reveal an urgent need to examine the efficacy of experimental treatments, such as neural transplantation, in order to develop better treatment therapies. This chapter will discuss the characteristics of NT2N cells, the role of the host brain microenvironment, the need for more rigorous laboratory research and clinical trials for the intracerebral transplantation of NT2N cells in stroke, the mechanisms underlying the grafts' beneficial effects, and the need for immunosuppression. This chapter will highlight some of the most recent findings regarding NT2N cells.",
keywords = "Cancer, Gene therapy, Intracerebral Transplantation, Nervous system, Neuron, Neuroprotection, Neuroteratocarcinoma Cells, NT2N, Review, Stroke, Therapeutic, Treatment, Tumor",
author = "Borlongan, {Cesario V.} and Christina Fournier and Stahl, {Christine E.} and Guolong Yu and Lin Xu and Noriyuki Matsukawa and Mary Newman and Takao Yasuhara and Koichi Hara and Hess, {David C} and Sanberg, {Paul R.}",
year = "2006",
month = "2",
day = "23",
doi = "10.2741/1865",
language = "English (US)",
volume = "11",
pages = "1090--1100",
journal = "Frontiers in Bioscience - Landmark",
issn = "1093-9946",
publisher = "Frontiers in Bioscience",
number = "1 P.889-1198",

}

TY - JOUR

T1 - Gene therapy, cell transplantation and stroke

AU - Borlongan, Cesario V.

AU - Fournier, Christina

AU - Stahl, Christine E.

AU - Yu, Guolong

AU - Xu, Lin

AU - Matsukawa, Noriyuki

AU - Newman, Mary

AU - Yasuhara, Takao

AU - Hara, Koichi

AU - Hess, David C

AU - Sanberg, Paul R.

PY - 2006/2/23

Y1 - 2006/2/23

N2 - The use of neuroteratocarcinoma cells for transplantation therapy in stroke has emerged as a strategy for cell replacement therapy that has begun its transition from basic science laboratories to a clinical setting. Procurement logistics and novel neuroprotective functions associated with these cells allow neuroteratocarcmoma cells to serve as efficacious alternatives to using fetal cells as donor cell grafts for stroke therapy, although the optimal transplantation regimen must still be determined. In particular, the limitations of current stroke treatments and management reveal an urgent need to examine the efficacy of experimental treatments, such as neural transplantation, in order to develop better treatment therapies. This chapter will discuss the characteristics of NT2N cells, the role of the host brain microenvironment, the need for more rigorous laboratory research and clinical trials for the intracerebral transplantation of NT2N cells in stroke, the mechanisms underlying the grafts' beneficial effects, and the need for immunosuppression. This chapter will highlight some of the most recent findings regarding NT2N cells.

AB - The use of neuroteratocarcinoma cells for transplantation therapy in stroke has emerged as a strategy for cell replacement therapy that has begun its transition from basic science laboratories to a clinical setting. Procurement logistics and novel neuroprotective functions associated with these cells allow neuroteratocarcmoma cells to serve as efficacious alternatives to using fetal cells as donor cell grafts for stroke therapy, although the optimal transplantation regimen must still be determined. In particular, the limitations of current stroke treatments and management reveal an urgent need to examine the efficacy of experimental treatments, such as neural transplantation, in order to develop better treatment therapies. This chapter will discuss the characteristics of NT2N cells, the role of the host brain microenvironment, the need for more rigorous laboratory research and clinical trials for the intracerebral transplantation of NT2N cells in stroke, the mechanisms underlying the grafts' beneficial effects, and the need for immunosuppression. This chapter will highlight some of the most recent findings regarding NT2N cells.

KW - Cancer

KW - Gene therapy

KW - Intracerebral Transplantation

KW - Nervous system

KW - Neuron

KW - Neuroprotection

KW - Neuroteratocarcinoma Cells

KW - NT2N

KW - Review

KW - Stroke

KW - Therapeutic

KW - Treatment

KW - Tumor

UR - http://www.scopus.com/inward/record.url?scp=32844463899&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=32844463899&partnerID=8YFLogxK

U2 - 10.2741/1865

DO - 10.2741/1865

M3 - Review article

VL - 11

SP - 1090

EP - 1100

JO - Frontiers in Bioscience - Landmark

JF - Frontiers in Bioscience - Landmark

SN - 1093-9946

IS - 1 P.889-1198

ER -